4/24
11:23 am
nbix
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth [Yahoo! Finance]
Low
Report
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth [Yahoo! Finance]
4/24
08:41 am
nbix
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community [Yahoo! Finance]
4/24
08:30 am
nbix
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Low
Report
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
4/24
08:10 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
4/24
08:10 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $200.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $200.00 price target on the stock.
4/24
07:04 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $170.00 price target on the stock, up previously from $140.00.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $170.00 price target on the stock, up previously from $140.00.
4/23
08:40 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/23
07:04 am
nbix
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder [Yahoo! Finance]
4/23
07:00 am
nbix
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Medium
Report
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
4/16
04:01 pm
nbix
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
Low
Report
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
4/16
07:19 am
nbix
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment [Yahoo! Finance]
Low
Report
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment [Yahoo! Finance]
4/16
02:43 am
nbix
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 [Yahoo! Finance]
Low
Report
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 [Yahoo! Finance]
4/10
04:01 pm
nbix
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Low
Report
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
4/10
10:19 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
4/3
11:06 am
nbix
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Performance Tethered To Its Attractive Financial Prospects? [Yahoo! Finance]
Low
Report
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Performance Tethered To Its Attractive Financial Prospects? [Yahoo! Finance]
4/3
08:42 am
nbix
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder [Yahoo! Finance]
4/3
08:30 am
nbix
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Low
Report
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
3/28
08:40 am
nbix
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults [Yahoo! Finance]
3/28
08:30 am
nbix
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Low
Report
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
3/20
08:08 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $148.00 to $158.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $148.00 to $158.00. They now have an "overweight" rating on the stock.
3/18
03:16 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $170.00 to $200.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $170.00 to $200.00. They now have an "outperform" rating on the stock.
3/11
04:01 pm
nbix
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Low
Report
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
3/1
09:58 am
nbix
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus [Yahoo! Finance]
Low
Report
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus [Yahoo! Finance]
3/1
12:53 am
nbix
Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company Shares [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company Shares [Yahoo! Finance]
2/27
04:01 pm
nbix
Neurocrine Biosciences to Participate at Investor Conferences in March
Low
Report
Neurocrine Biosciences to Participate at Investor Conferences in March